Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Clinical Trial for Patients with Advanced Cancers Recruiting

2024-515020-36-00 Advanced Solid tumour 9 2025-02-24
A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma Recruiting

2024-515316-44-00 Multiple Myeloma 3 2025-02-24
Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in p… Recruiting

2024-514031-20-00 Inoperable locally advanced or metastatic TNBC patients 4 2025-02-24
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients … Recruiting

2023-507754-33-00 steroid-refractory chronic Graft-versus-Host-Disease 4 2025-02-19
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refrac… Recruiting

2024-520436-15-00 High Risk and/or relapsed/refractory Neuroblastoma and 7 2025-02-18
Open-label study of Asciminib for CML-CP or CML-AP patients with T315I mutation who are resistant, intolerant or ineligible to ponatinib Recruiting

2024-516049-38-00 CML-CP or CML-AP patients with T315I mutation 4 2025-02-18
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
FAPIDO Recruiting

2024-512059-19-00 Diverse oncological patients with a clinically challeng 10 2025-02-14
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No… Recruiting

2023-509806-31-00 Non-Small Cell Lung Cancer 4 2025-02-11
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Recurrent or Metastatic Solid Tumors (endometrial cance 9 2025-02-11
Clinical trial on the use of metformin in addition to standard therapy in patients with high-grade glioma Recruiting

2024-520228-28-00 IDH-wildtype glioblastoma 4 2025-02-10
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and it… Recruiting

2023-508126-95-00 The target population of the trial consists of patients 1 2025-02-10
Preparation for bone marrow transplantation through the combined use of chemo and radiotherapy (Reduced intensity: with lower doses or diffe… Recruiting

2024-514483-11-00 High-Risk Myelodisplastic Syndrome OR Acute Myeloid Leu 4 2025-02-10
Preparation for bone marrow transplant through the combined use of chemo and radiotherapy (intensive or myeloablative: eliminates stem cells… Recruiting

2024-514484-25-00 High-Risk Myelodisplastic Syndrome or Acute Myeloid Leu 4 2025-02-10
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Ozone treatment in patients with numbness and/or tingling secondary to chemotherapy. Randomized clinical trial. Recruiting

2024-517196-20-00 Paresthesia (numbness, tingling) secondary to chemother 10 2025-02-07
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting

2024-516440-25-00 KRAS G12D-mutant solid tumors. 1 2025-02-06
Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory… Recruiting

2024-519168-42-00 Relapsed/refractory malignant central nervous system tu 3 2025-02-05
A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Recruiting

2024-513199-16-00 Relapsed or Refractory Acute Myeloid Leukemia or Relaps 1 2025-02-04
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Resectable Non-small cell lung cancer 5 2025-02-04
A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma Recruiting

2024-519437-27-02 Glioblastoma 5 2025-02-03